Amanote Research
Register
Sign In
Prostaglandins I2 and E1 and Red Cell Deformability in Raynaud's Phenomenon and Systemic Sclerosis
BMJ
doi 10.1136/bmj.283.6306.1609
Full Text
Open PDF
Abstract
Available in
full text
Date
December 12, 1981
Authors
P. Dowd
Publisher
BMJ
Related search
Effect of Prostaglandins I2 and E1 on Red Cell Deformability in Patients With Raynaud's Phenomenon and Systemic Sclerosis.
BMJ
Infusion of Iloprost, a Prostacyclin Analogue, for Treatment of Raynaud's Phenomenon in Systemic Sclerosis.
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Recount of Prostaglandin E1 Therapy in a Patient With Raynaud's Phenomenon
Journal of the American Osteopathic Association, The
Medicine
Alternative Medicine
Complementary
Autohaemagglutination and Raynaud's Phenomenon
BMJ
Raynaud's Phenomenon
Nurse Prescribing
A Woman With Dysphagia and Raynaud's Phenomenon
Postgraduate Medical Journal
Medicine
Assessment and Management of Raynaud's Phenomenon
Prescriber
Pharmacology
Pulse Cyclophosphamide Decreases Sympathetic Postganglionic Activity, Controls Alveolitis, and Normalizes Vascular Tone Dysfunction (Raynaud's Phenomenon) in a Case of Early Systemic Sclerosis
Arthritis Care & Research
Plasma Urotensin II Levels in Primary Raynaud’s Phenomenon and Systemic Sclerosis
Turkish Journal of Medical Sciences
Medicine
